Interviews

Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses how oncology biosimilars will impact financial toxicity.

Alexandra Valenti, JD, associate at Goodwin, discusses a recent case in which one biosimilar developer sued another over adalimumab.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses biosimilar education.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, explains how rheumatology specialists have led the way in biosimilar adoption.

Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses the adoption of oncology biosimilars.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how biosimilar savings have been put to use by the NHS.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, discusses whether the Danish biosimilars market is sustainable.

Alexandra Valenti, JD, associate at Goodwin, discusses how Biologics Price Competition and Innovation Act (BPCIA) litigation has evolved with greater experience.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses biosimilars and misinformation.

Bruce Sherman, MD, FCCP, FACOEM, chief medical officer of the National Alliance for Healthcare Purchaser Coalitions, discusses how biosimilars will play a role in controlling high drug costs for employers.

Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses whether the US patent system is likely to see reform in the near future.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how she coordinates with providers on biosimilar switching programs.

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses ongoing research on biosimilar rituximab, Rixathon.

Kashyap Patel, MD, discusses how biosimilars impact cost in the Medicare Part B context.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Denmark has engaged with patients on biosimilars.

Alexandra Valenti, JD, associate at Goodwin, discusses the future of the Biologics Price Competition and Innovation Act (BPCIA) in light of challenges to the Affordable Care Act.

Rolf Benirschke, chief executive officer of Legacy Health Strategies, discusses the challenges patients face in getting access to biologics to treat inflammatory bowel disease.

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the impact that biosimilars have made on patient access to therapy.

Kashyap Patel, MD, discusses the need for provider education on biosimilars.

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the benefits that biosimilars have in terms of patient access.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the need for ongoing provider education about biosimilars.

Simon Rule, MD, Plymouth University Medical School, discusses how subcutaneous rituximab has impacted clinical practice.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how the NHS has overcome hurdles related to switching to biosimilars.

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the role of real-world evidence for biosimilar trastuzumab.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, addresses whether challenges lie ahead for biosimilars in Denmark.

Suzette Kox, MPharm, secretary general of the International Generic and Biosimilar Medicines Association (IGBA), discusses the need to waive bridging studies in biosimilar development.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar granulocyte colony-stimulating factor (G-CSF) therapies have impacted cancer care.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the state of the EU biosimilars market.

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the rationale for gathering real-world evidence on biosimilar rituximab.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses areas where pharmacists still have questions about biosimilars and their implementation.